Sibeprenlimab clinical trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy

This study is testing a new medicine called sibeprenlimab for people with a kidney condition called IgA nephropathy. Researchers want to see if this medicine can help improve kidney function and reduce protein in the urine, compared to a dummy medicine.